GlycoNex Incorporation (TPEX:4168)

Market Cap	2.84B -1.1%
Revenue (ttm)	36.35M +91.0%
Net Income	-266.56M
EPS	-2.43
Shares Out	112.52M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	161,868
Open	25.65
Previous Close	25.65
Day's Range	25.10 - 25.65
52-Week Range	20.55 - 30.00
Beta	0.58
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 13, 2026

About GlycoNex Incorporation

GlycoNex Incorporation engages in the development of cancer drugs using glycosphingolipid antigen and human monoclonal antibody technologies in Japan and Taiwan. The company’s pipeline under the BLA stage consists of SPD8-P, a Prolia biosimilar for the treatment of osteoporosis; and SPD8-R, a Xgeva biosimilar for the treatment of bone cancer metastases. It also develops GNX102, a humanized monoclonal antibody, which is in Phase 1 clinical trials for the treatment of various solid tumor types, such as colorectal, gastric, lung, breast, and pancr...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4168

Financial Performance

In 2025, GlycoNex Incorporation's revenue was 37.86 million, an increase of 157.54% compared to the previous year's 14.70 million. Losses were -235.23 million, 2.40% more than in 2024.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jul 9, 2026

Data Sources Report a data error